<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700724</url>
  </required_header>
  <id_info>
    <org_study_id>151898</org_study_id>
    <nct_id>NCT02700724</nct_id>
  </id_info>
  <brief_title>Observation Versus Immediate Surgery of Low Risk Bladder Cancer</brief_title>
  <official_title>Observation Versus Immediate Surgery of Low Risk Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, multi-center, non-inferiority study comparing observation versus
      immediate surgery for low grade, noninvasive bladder cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>An event is a complication of any kind, including bleeding requiring blood transfusion, bladder perforation, urinary tract infection, readmission to the hospital, and progression of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with disease progression (either stage or grade)</measure>
    <time_frame>12 months</time_frame>
    <description>proportion of patients with disease progression (either stage or grade)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Costs</measure>
    <time_frame>At baseline and 3 months, 6 months, 9 months and 12 months.</time_frame>
    <description>out of pocket medical costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported patient anxiety measured using the EORTC QLQ-NMIBC24</measure>
    <time_frame>At baseline and 3 months, 6 months, 9 months and 12 months.</time_frame>
    <description>Measured using the EORTC QLQ-NMIBC24, which is a 24-item questionnaire for patients with superficial bladder cancer. This will be assessed at baseline and every 3 months during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immediate Surgery</intervention_name>
    <arm_group_label>Immediate Surgery</arm_group_label>
    <other_name>Transurethral Resection of Bladder Tumor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <arm_group_label>Observation</arm_group_label>
    <other_name>Active Surveillance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surveillance Cystoscopy and Urinary Cytology</intervention_name>
    <description>Cytology and cystoscopy are done at the same time</description>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_label>Immediate Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of low grade, noninvasive urothelial carcinoma of the bladder with a new
             recurrence that meets the following criteria:

          -  total tumor burden â‰¤3cm in size (multiple lesions permitted)

          -  low grade appearance (grade 1 or grade 2)

          -  noninvasive appearance (Ta)

          -  no history of carcinoma in situ (CIS) or lesions concerning for CIS

          -  negative urine cytology (atypical or suspicious for low grade neoplasm are acceptable)

        Exclusion Criteria:

          -  High grade and/or invasive and/or carcinoma in situ disease

          -  Concomitant upper tract urothelial carcinoma

          -  Any patient who is pregnant or who may have plans to become pregnant.

          -  Positive cytology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel D. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Lee, MD</last_name>
    <email>daniel.lee.1@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2016</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Lee</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

